C4 Therapeutics (CCCC) Current Leases (2019 - 2026)

C4 Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• On a quarterly basis, Current Leases rose 10.19% year-over-year to $6.5 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 10.19% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, up 10.27% from the prior year.
• Current Leases climbed to $6.5 million in Q1 2026 per CCCC's latest filing, from $6.4 million in the prior quarter.
• Across five years, Current Leases topped out at $6.5 million in Q1 2026 and bottomed at $1.7 million in Q1 2022.
• The 5-year median for Current Leases is $5.4 million (2024), against an average of $5.1 million.
• Across the five-year window, Current Leases surged 288.87% in 2022 and gained 10.19% in 2026, its largest moves.
• Year by year, Current Leases stood at $4.7 million in 2022, then advanced by 11.04% to $5.2 million in 2023, then advanced by 10.63% to $5.8 million in 2024, then gained by 10.27% to $6.4 million in 2025, then increased by 2.43% to $6.5 million in 2026.
• Per Business Quant, the three latest CCCC Current Leases figures stand at $6.5 million (Q1 2026), $6.4 million (Q4 2025), and $6.2 million (Q3 2025).